JHP Pharmaceuticals, has entered into an agreement with an undisclosed biotech company to produce clinical trial batches of an innovative drug used in the treatment of heart failure.
Stuart Hinchen, President and CEO of JHP stated, “We are pleased that JHP was chosen to produce clinical batches for this important customer. Our cGMP compliance record, coupled with an experienced staff, gives us an advantage in meeting customer needs throughout a product’s life cycle, starting with clinical batch production.”
“We know that customers want to seamlessly transition from clinical batch production to product launch and then commercialization. JHP has the right scale and experience to meet customer needs across the product life cycle.”
Hinchen also noted, “During the last seven months, we successfully completed FDA and EMA audits and entered agreements with five new customers. These agreements are examples of how our approach to continuing investment allows us to focus on customer needs, which results in an internal infrastructure that supports ongoing sustainable growth.”
JHP’s Rochester, Michigan manufacturing site has a solid history of successful partnerships, manufacturing clinical and commercial products.